skip to Main Content

Pancreatic Cancer: Data With Liposomal Irinotecan/5-FU

Newsfeed image, light gray text on dark gray background
New drug development in pancreas cancer has been very interesting for almost 10 years. After gemcitabine’s original approval, we kept trying to put everything with gemcitabine. “This,” with gemcitabine. “That,” with gemcitabine. Even taxanes with gemcitabine. It really didn’t help until we used a liposomal taxane, which is nab-paclitaxel (Abraxane).

Insights From: Fadi Braiteh, MD, University of Nevada School of Medicine; John L. Marshall, MD, Georgetown University Hospital ; Kenneth H. Yu, MD, Memorial Sloan Kettering Cancer Center.  Listen here . . .

Back To Top